Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(3):175; doi:10.1093/jnci/92.3.175
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 3, 175, February 2, 2000
© 2000 Oxford University Press

IN THIS ISSUE

High-Dose Chemotherapy and Breast Cancer

Hortobagyi et al. (p. 225) have conducted a prospective randomized trial involving women with high-risk (of relapse) breast cancer to compare the outcomes of patients treated with standard-dose chemotherapy and patients treated with the same therapy followed by high-dose chemotherapy. Seventy-eight women received eight cycles of 5-fluorouracil, doxorubicin, and cyclophosphamide. They were then randomly assigned to receive no further treatment or to receive two cycles of high-dose cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support (bone marrow transplantation). The authors report no relapse-free . . . [Full Text of this Article]

New Treatment Response Guidelines

Indanocine: Antimitotic Agent and Inducer of Apoptosis

Reminder Calls and Screening Mammograms

Coumarin Antibiotics and Heat Shock Protein 90

Talc Use and Ovarian Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?